Roche said that FDA has granted accelerated review to Avastin drug as a treatment for glioblastoma, the most dangerous form of brain cancer.

In its endeavor to take complete control of the biotech Genentech Inc, after an eight-month association, Roche Holding AG has upped its buyout deal - for the 44 percent of the company it doesn't already own - to $46.7 billion, a 2 percent increase over its earlier offer.

Switzerland-based Roche Pharmaceuticals has signed a definitive merger agreement with Nasdaq-listed Memory Pharmaceuticals to acquire all the outstanding shares of latter, in an all-cash transaction for an aggregate price of approximately USD 50 million.